RXi’s CEO Resigns as Company Looks to Clinic, Industry Partnerships

The change follows a number of false starts RXi has made in regard to its pipeline, as well as the firm’s failure to meet previously stated partnering goals. But RXi is not alone in this respect, and management changeups in troubled times have been par for the course among RNAi drug shops.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.